Vaxcyte Inc. (NASDAQ: PCVX) stock jumped 0.29% on Tuesday to $45.13 against a previous-day closing price of $45.00. With 0.5 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.39 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $45.70 whereas the lowest price it dropped to was $44.40. The 52-week range on PCVX shows that it touched its highest point at $49.31 and its lowest point at $16.78 during that stretch. It currently has a 1-year price target of $63.29.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PCVX was up-trending over the past week, with a rise of 0.45%, but this was down by -2.90% over a month. Three-month performance surged to 119.29% while six-month performance rose 93.03%. The stock gained 158.48% in the past year, while it has lost -5.88% so far this year. A look at the trailing 12-month EPS for PCVX yields -2.95 with Next year EPS estimates of -3.02. For the next quarter, that number is -0.84. This implies an EPS growth rate of 36.20% for this year and 6.80% for next year.
Float and Shares Shorts:
At present, 78.98 million PCVX shares are outstanding with a float of 71.64 million shares on hand for trading. On Oct 13, 2022, short shares totaled 3.2 million, which was 5.40% higher than short shares on Sep 14, 2022. In addition to Mr. Grant E. Pickering M.B.A. as the firm’s Co-Founder, CEO & Director, Mr. Andrew L. Guggenhime M.B.A. serves as its Pres & CFO.
Through their ownership of 92.57% of PCVX’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 43.40% of PCVX, in contrast to 3.75% held by mutual funds. Shares owned by individuals account for 11.12%. As the largest shareholder in PCVX with 11.09% of the stake, Fidelity Management & Research Co holds 8,759,076 shares worth 8,759,076. A second-largest stockholder of PCVX, RA Capital Management LP, holds 4,581,203 shares, controlling over 5.80% of the firm’s shares. Janus Henderson Investors US LLC is the third largest shareholder in PCVX, holding 4,533,741 shares or 5.74% stake. With a 3.21% stake in PCVX, the American Funds Small Cap World Fu is the largest stakeholder. A total of 2,531,043 shares are owned by the mutual fund manager. The Vanguard Total Stock Market Index, which owns about 2.75% of PCVX stock, is the second-largest Mutual Fund holder. It holds 2,174,250 shares valued at 104.26 million. SPDR S&P Biotech ETF holds 2.36% of the stake in PCVX, owning 1,867,183 shares worth 89.53 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PCVX since 8 analysts follow the stock currently. There are 7 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With PCVX analysts setting a high price target of $70.00 and a low target of $56.00, the average target price over the next 12 months is $63.29. Based on these targets, PCVX could surge 55.11% to reach the target high and rise by 24.09% to reach the target low. Reaching the average price target will result in a growth of 40.24% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. PCVX will report FY 2022 earnings on 02/27/2024. Analysts have provided yearly estimates in a range of -$3.20 being high and -$3.31 being low. For PCVX, this leads to a yearly average estimate of -$3.24. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Vaxcyte Inc. surprised analysts by -$0.09 when it reported -$0.93 EPS against a consensus estimate of -$0.84. The surprise factor in the prior quarter was -$0.11. Based on analyst estimates, the high estimate for the next quarter is -$0.78 and the low estimate is -$0.94. The average estimate for the next quarter is thus -$0.84.
Summary of Insider Activity:
Insiders traded PCVX stock several times over the past three months with 6 Buys and 6 Sells. In these transactions, 152,890 shares were bought while 18,670 shares were sold. The number of buy transactions has increased to 42 while that of sell transactions has risen to 78 over the past year. The total number of shares bought during that period was 485,055 while 325,203 shares were sold.